Table 3.
Some of the polymeric nanoparticle formulations that have been recently explored.
| Type | Drug | Targeting Agent | Name of Polymer Used | Result | Reference |
|---|---|---|---|---|---|
| Polymeric nanoparticle | Cisplatin | Cytokeratin-specific monoclonal antibody | Poly(d,l-lactide-co-glycolide) and polyethene glycol | Prevent metastasis | [115] |
| Polymeric nanoparticle | Paclitaxel | Monoclonal antibodies (antiHERT2) | Poly(d,l-lactic acid) | Selective targeting | [116] |
| Polymeric nanoparticle | Paclitaxel | Folic acid | Polylactic acid and polyethylene glycol | Enhanced drug accumulation in tumor | [117] |
| Polymer micelle | Doxorubicin | Folic acid | PEG-co-poly(lactic-co-glycolic acid) | Increased cellular uptake and cytotoxicity | [118] |
| Polymer micelle | Doxorubicin | Folic acid | PEG-poly(aspartate hydrazine doxorubicin) | Increased endocytotic cellular uptake | [118] |
| Polymeric nanoparticle | Doxorubicin | Cyclo-(1,12)-penITDGEATDGC (cLABL) |
PGLA Poly d,l-lactic-co-glycolic acid |
It showed enhanced cellular uptake | [119] |
| Polymeric nanoparticle | Mitomycin | Folic acid | mPEG poly(ethylene glycol) methyl ether |
Targeted cellular uptake and enhanced tumor tissue distribution of the drug were achieved | [120] |